Dow Corning breast implant report
This article was originally published in The Gray Sheet
Executive Summary
Judge Samuel Pointer of the U.S. District Court in Birmingham, Alabama rules that the report prepared by former Attorney General Griffen Bell on the company's breast implant business is confidential under the attorney/client relationship and does not have to be released to the public or FDA, according to Dow. The agency had asked the company to release the report ("The Gray Sheet" Jan. 18, I&W-4). Judge Pointer, who has multi-district responsibility for silicone breast implant lawsuits, rendered the decision at a recent pre-trial conference in Washington, D.C. The next conferences are scheduled for Feb. 24 in San Francisco and March 25 in Birmingham, Alabama.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.